Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001957912-26-000020
Filing Date
2026-05-12
Accepted
2026-05-12 17:17:44
Documents
2
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8210
2 ex1.htm EX-1 6420
  Complete submission text file 0001957912-26-000020.txt   16419
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Subject) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90539 | Film No.: 26969879
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 3155 W. BIG BEAVER ROAD, SUITE 207 TROY MI 48084
Business Address 3155 W. BIG BEAVER ROAD, SUITE 207 TROY MI 48084 (734) 649-4634
Baselake Partners, LP (Filed by) CIK: 0001957912 (see all company filings)

EIN.: 920901824 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A